Abeona Q1 FY26 net product revenue more than doubled to $8.7 million; SG&A rises to $19.5 million

Abeona Therapeutics, Inc.

Abeona Therapeutics, Inc.

ABEO

0.00
  • Abeona Therapeutics posted Q1 2026 net product revenue of USD 8.7 million, up from USD 2.4 million in Q4 2025.
  • Cost of sales rose to USD 2.7 million from USD 1 million, while SG&A expenses climbed to USD 19.5 million from USD 9.8 million a year earlier.
  • R&D expenses totaled USD 9.6 million, including a USD 7 million license payment for the PSMA SIR-T asset.
  • Cash, cash equivalents, and short-term investments were USD 168.3 million as of March 31, 2026.
  • ZEVASKYN adoption expanded with six Qualified Treatment Centers activated, three patients treated in Q1 2026, and 100+ potential patients identified across QTCs and non-QTC physicians as of May 13, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.